Jefferies Upgrades AveXis (AVXS) to Buy
Find out which companies are about to raise their dividend well before the news hits the Street with StreetInsider.com's Dividend Insider Elite. Sign-up for a FREE trial here.
Jefferies upgraded AveXis (NASDAQ: AVXS) from Hold to Buy with a price target of $42.00.
Analyst Biren Amin commented, "AVXS reported updated SMA Type 1 data today in conjunction with earnings. The data continued to show no events in the therapeutic dose cohort and improving CHOP-INTEND scores. With this continued efficacy data along w/ positive feedback from an expert dinner suggesting that FDA may allow for a single-arm pivotal trial in SMA Type 1, we are upgrading to Buy."
Shares of AveXis closed at $34.80 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Jefferies Cuts Price Target on ResMed (RMD) to $56 Following 1Q Miss
- FBR Capital Upgrades Akamai Technologies (AKAM) to Market Perform
- Apple (AAPL): Pokemon Go and Samsung Drove Upside - Needham
Create E-mail Alert Related CategoriesAnalyst Comments, Upgrades
Related EntitiesJefferies & Co, Earnings
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!